Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

Inclusion Criteria:

* Patients with invasive epithelial ovarian, fallopian tube or peritoneal cancer, being resistant to treatment with platinum and a taxane, either given in combination or sequentially.
* Patients with clinical progression during or within 6 months after end of treatment for primary disease or relapse.
* Patients with stable disease after 6 courses of chemotherapy for primary disease or relapse if further treatment is indicated.
* Patients with doubling of s-CA 125 to at least 70 IU/Ml within 3 months after end of treatment for primary disease or relapse.
* Age must be at least 18 years.
* Performance status must be 0-2 (WHO/ECOG, appendix 1).
* Informed consent given according to ICH/EU GCP guidelines and local or national laws

Exclusion Criteria:

* Patients with symptomatic brain metastasis
* Bilirubin greater than 2 x UNL (upper normal limits), white blood cell count below 3.0 x 109/L, neutrophil count below 1.5 x 109/L, platelets count below 100 x 109/L.
* Active infection or other serious underlying medical condition which might prevent the patient from receiving treatment or to be followed.
* Pregnant, lactating, or child bearing potential patients without adequate contraception
* Previous treatment with Tamoxifen.